Every Form 4 that Nuvalent, Inc. (NUVL) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow NUVL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NUVL filings page.
Nuvalent, Inc. Chief Scientific Officer Henry E. Pelish reported a mix of stock sales and new equity awards. On January 5–6, 2026, he sold multiple blocks of Nuvalent Class A Common Stock in open-market transactions, including 513 shares at a weighted average price of $96.06, 660 shares at $96.85, 1,137 shares at $97.96, 186 shares at $98.52, 1,106 shares at $96.75, 1,369 shares at $97.33 and 189 shares at $98.40.
According to the footnotes, these sales were made under a durable Rule 10b5-1 sell-to-cover instruction entered into on December 6, 2023 to satisfy tax withholding obligations on vesting equity awards. On January 7, 2026, Pelish acquired 17,500 shares of Class A Common Stock for $0.00 pursuant to restricted stock units that vest in three equal annual installments after January 7, 2026, and received a stock option for 17,500 shares with an exercise price of $106.82, vesting in equal monthly installments over four years.
Nuvalent, Inc. Chief Development Officer Darlene Noci reported several sales and equity awards involving the company’s Class A Common Stock. On January 5 and 6, 2026, she sold multiple small blocks of shares under a durable Rule 10b5-1 sell-to-cover instruction entered into on December 6, 2023 to satisfy tax withholding obligations upon vesting of earlier equity awards. Reported weighted average sale prices include $96.06, $96.85, $97.96 and $98.52 per share.
On January 7, 2026, Noci reported an acquisition of 17,500 Class A shares for $0.00 per share, representing restricted stock units that vest in three equal annual installments following that date, subject to continued service. She also received a stock option for 17,500 shares at an exercise price of $106.82 per share, vesting in equal monthly installments over four years after January 7, 2026. Following these transactions, she directly owned 58,117 Class A shares and 17,500 stock options.
Nuvalent, Inc. Chief Legal Officer Deborah Ann Miller reported multiple transactions in the company’s Class A Common Stock. On January 5–6, 2026, she sold several small blocks of shares at weighted average prices generally ranging from about $95.34 to $99.10 per share, with the filing noting these sales were made under a durable Rule 10b5-1 sell-to-cover instruction to satisfy tax withholding obligations on previously granted equity awards.
On January 7, 2026, she received 17,500 restricted stock units (RSUs), each representing one share of Class A Common Stock, which vest in three equal annual installments following that date, and a stock option for 17,500 shares at an exercise price of $106.82 that vests in equal monthly installments over four years. After these transactions, she directly beneficially owned 59,634 shares of Class A Common Stock and 17,500 stock options.
Nuvalent, Inc. Chief Medical Officer Christopher Durant Turner reported multiple sales of Class A common stock on January 5–6, 2026, at weighted average prices generally in the $96–$99 range. The filing notes these sales were executed under a durable Rule 10b5-1 sell-to-cover instruction entered into on December 6, 2023 to cover tax withholding on previously vested equity awards.
On January 7, 2026, he reported the acquisition of 17,500 restricted stock units (RSUs), each representing one share of Class A common stock, which vest in three equal annual installments following January 7, 2026, subject to continued service. He also received a stock option for 17,500 shares with an exercise price of $106.82, vesting in equal monthly installments over four years following January 7, 2026.
Nuvalent, Inc. Chief Financial Officer Alexandra Balcom reported several transactions in the company’s Class A common stock. On January 5 and 6, 2026, she sold small blocks of shares at weighted average prices ranging from about $95 to $99 per share under a durable Rule 10b5-1 sell-to-cover instruction, used to satisfy tax withholding on previously granted equity awards. After these sales, she continued to hold tens of thousands of shares directly.
On January 7, 2026, Balcom received 17,500 restricted stock units, each representing one share of Nuvalent Class A common stock. These RSUs vest in three equal annual installments following January 7, 2026, subject to continued service. She was also granted a stock option for 17,500 shares at an exercise price of $106.82 per share, vesting in equal monthly installments over four years following January 7, 2026, also conditioned on continued service.
Nuvalent, Inc. President and CEO James Richard Porter reported multiple stock transactions in early January 2026. On January 5–6, 2026, he sold several blocks of Nuvalent Class A Common Stock under a pre-arranged Rule 10b5-1 sell-to-cover instruction, with weighted average prices ranging from about $96 to $99 per share to cover tax withholding on previously vested equity awards. After these sales, his directly held shares were reduced to 278,629.
On January 7, 2026, Porter received 46,250 restricted stock units (RSUs) for Class A Common Stock at a stated price of $0.00, increasing his directly held shares to 324,879. The RSUs vest in three equal annual installments following January 7, 2026, subject to continued service. He was also granted a stock option for 46,250 shares at an exercise price of $106.82 per share, vesting in equal monthly installments over four years after January 7, 2026.
Nuvalent, Inc. reported that one of its directors acquired equity on December 10, 2025. The director received 2,837 shares of Class A common stock issuable under restricted stock units at a price of $0.00, bringing direct ownership of Class A common stock to 2,837 shares.
The director also acquired a stock option for 4,418 shares of Class A common stock with an exercise price of $105.74 and an expiration date of December 10, 2035. The RSUs vest in three equal annual installments after December 10, 2025, while the stock option vests over the three years following that date in equal monthly installments, in each case subject to continued service.
Nuvalent, Inc. (NUVL) reported insider stock sales by a director on 11/24/2025. The reporting person sold multiple small blocks of Class A common stock in open-market transactions under a pre-arranged Rule 10b5-1 trading plan adopted on November 20, 2024.
The Form 4 shows sales at weighted average prices ranging from about $107.01 to $110.64 per share, including transactions reported at weighted averages of $107.70, $108.73, $109.77 and $110.42. After these transactions, the reporting person beneficially owned 1,378,387 Class A common shares directly and 201,672 shares indirectly through the Matthew D. Shair 2021 Irrevocable Family Trust, over which the reporting person has voting and dispositive power.
Nuvalent, Inc. (NUVL) reported an insider transaction by a group of affiliated investment funds and entities that are directors, 10% owners, and directors by deputization. On 11/24/2025, Deerfield Private Design Fund IV, L.P. and Deerfield Healthcare Innovations Fund, L.P. each reported selling 371,287 shares of Nuvalent Class A common stock pursuant to the exercise of underwriters' option to cover over-allotments in an underwritten public offering at a price of $95.445 per share, while the shares were sold to the public at $101.00 per share. Following the reported transactions, the filing shows 8,299,225 shares of Class A common stock beneficially owned indirectly through Deerfield Private Design Fund IV, L.P. and Deerfield Healthcare Innovations Fund, L.P., and 650,000 shares indirectly through Deerfield Partners, L.P. The reporting persons state they disclaim beneficial ownership beyond their indirect pecuniary interest.
Nuvalent, Inc. (NUVL) filed a Form 4 for its Chief Financial Officer detailing option exercises and stock sales in November 2025. On November 17, 2025, the CFO exercised stock options for 6,875 Class A shares at $6.89 and 13,125 shares at $72.35, then sold multiple blocks of Class A Common Stock at weighted average prices ranging from $93.8 to $103.68. On November 18, 2025, additional options for 729 shares at $72.35 were exercised, with share sales at weighted average prices of $103.61 and $104.54. After these transactions, the CFO directly owned 61,734 Class A shares and held stock options covering 29,101 and 33,646 shares. All reported trades were made under a Rule 10b5-1 trading plan adopted on December 12, 2024.
Nuvalent, Inc. (NUVL) reported insider activity by its Chief Legal Officer on a Form 4. On 11/17/2025, the officer exercised a stock option for 24,200 shares of Class A common stock at an exercise price of $6.89 per share. That same day, the officer sold 15,075 shares at a weighted average price of $105.16, 8,517 shares at $105.98, and 608 shares at $107.04, all under a Rule 10b5-1 trading plan adopted on November 18, 2024. After these transactions, the officer directly owned 49,086 shares of Class A common stock and held 94,608 stock options that remain beneficially owned, with the option covering 24,200 shares fully vested and expiring on 04/29/2031.